NCT07076030View on ClinicalTrials.gov

Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

November 25, 2025

Study Completion Date

December 31, 2025

Conditions
Renal Impairment
Interventions
DRUG

Petrelintide

Solution administered with a syringe

Trial Locations (1)

2860

RECRUITING

Zealand Pharma, Søborg

Sponsors

Lead Sponsor

Zealand Pharma

Collaborators (1)

ICON plc
All Listed Sponsors
collaborator

ICON plc

INDUSTRY

lead

Zealand Pharma

INDUSTRY

NCT07076030 - Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function | Biotech Hunter | Biotech Hunter